Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BERRY GLOBAL GROUP, INC.BERY · Entity 80192 | Director | November 25, 2023 | November 28, 2023 |
| Edwards Lifesciences CorpEW · Entity 3026 | CVP, Chief Financial Officer | May 11, 2026 | May 12, 2026 |
| ILLUMINA, INC.ILMN · Entity 3137 | Director | September 30, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BERRY GLOBAL GROUP, INC.
Report date November 25, 2023 · Filed November 28, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,728 |
Reported balance
After 2023-11-25 transaction · row 1
1 source rowRow 1 · 2023-11-25 · Exercise / conversion · Acquired 1,970 · Balance 4,728 F1: Each restricted stock unit represents a contingent right to receive one share of BERY common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,393 |
Reported balance
After 2023-11-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-11-25 · Exercise / conversion · Disposed 1,970 · Balance 1,393 F1: Each restricted stock unit represents a contingent right to receive one share of BERY common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F2: The award was granted on November 25, 2022 and vested in full on November 25, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of BERY common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.
F2: The award was granted on November 25, 2022 and vested in full on November 25, 2023.
Edwards Lifesciences Corp
Report date May 11, 2026 · Filed May 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 46,740 |
Ending reported balance
After 2026-05-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-11 · Exercise / conversion · Acquired 19,830 · Balance 57,744 F1: On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4. Row 2 · 2026-05-11 · Tax withholding · Disposed 11,004 · Balance 46,740 |
| Performance RightsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-11 · Exercise / conversion · Disposed 19,830 · Balance 0 F1: On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4. F2: These Performance Rights expire on May 10, 2030. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 266,318 |
Reported balance
Holding disclosure · report date 2026-05-11 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 266,318 |
Filing footnotes · ownership attribution and instrument terms
F1: On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4.
F2: These Performance Rights expire on May 10, 2030.
ILLUMINA, INC.
Report date September 30, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,143 |
Reported balance
After 2026-09-30 transaction · row 1
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 113 · Balance 11,143 F1: Mr. Ullem elected to receive 100% of his 2026 board and committee cash retainer fees in Illumina stock. The number of shares issued in lieu of cash is based on the quotient of (i) the cash compensation otherwise payable for the immediately completed quarter divided by (ii) the volume weighted average closing price per share during the immediately completed quarter, calculated by reference to each trading day during such quarter. The amount reported on this Form represents Mr. Ullem's 3rd quarter 2026 retainer fees. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Ullem elected to receive 100% of his 2026 board and committee cash retainer fees in Illumina stock. The number of shares issued in lieu of cash is based on the quotient of (i) the cash compensation otherwise payable for the immediately completed quarter divided by (ii) the volume weighted average closing price per share during the immediately completed quarter, calculated by reference to each trading day during such quarter. The amount reported on this Form represents Mr. Ullem's 3rd quarter 2026 retainer fees.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 04, 2022 Filed May 5, 2022 21:51 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 15,488 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006582 · doc4.xml · nonDerivative · entry 4 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 244,739 Read SEC document |
| April 04, 2022 Filed May 5, 2022 21:51 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 15,488 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006582 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,324 Read SEC document |
| February 21, 2022 Filed Feb 22, 2022 23:36 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 319 | $105.62 | $33,692.78 |
DisclosureSEC source: 0001225208-22-002983 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,812 Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 22:05 UTC | BERRY GLOBAL GROUP, INC. BERY · Entity 80192 | GrantDirector Stock Option (Right to Buy) · Derivative | 3,497 | $0.00 Strike: $66.47 | $0.00 |
DisclosureSEC source: 0001567619-21-021300 · doc1.xml · derivative · entry 2 Ullem Scott B. · CIK 0001446989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,997 Underlying: Common Stock · 3,497 shares Expires 2031-11-26 F3 · derivative.exercise_date: Granted under the 2015 Long-Term Incentive Plan. Options vest in full on the first anniversary of the grant date. Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 22:05 UTC | BERRY GLOBAL GROUP, INC. BERY · Entity 80192 | GrantRestricted Stock Units · Derivative | 1,091 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-021300 · doc1.xml · derivative · entry 1 Ullem Scott B. · CIK 0001446989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,758 Underlying: Common Stock · 1,091 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of BERY common stock. Granted under the 2015 Long-Term Incentive Plan. F2 · derivative.exercise_date: The restricted stock units vest in full on the first anniversary of the grant date. Shares of BERY common stock will be delivered to the reporting person within 60 days following the date on which the restricted stock units vest. F2 · derivative.expiration_date: The restricted stock units vest in full on the first anniversary of the grant date. Shares of BERY common stock will be delivered to the reporting person within 60 days following the date on which the restricted stock units vest. Read SEC document |
| November 23, 2021 Filed Nov 29, 2022 21:58 UTC | BERRY GLOBAL GROUP, INC. BERY · Entity 80192 | Exercise / conversionRestricted Stock Units · Derivative | 1,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-021009 · doc1.xml · derivative · entry 3 Ullem Scott B. · CIK 0001446989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of BERY common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · price: Each restricted stock unit represents a contingent right to receive one share of BERY common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F2 · derivative.exercise_date: The award was granted on November 23, 2022 and vested in full on November 23, 2021. F2 · derivative.expiration_date: The award was granted on November 23, 2022 and vested in full on November 23, 2021. Read SEC document |
| November 23, 2021 Filed Nov 29, 2022 21:58 UTC | BERRY GLOBAL GROUP, INC. BERY · Entity 80192 | Exercise / conversionCommon Stock | 1,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-021009 · doc1.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of BERY common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Read SEC document |
| May 17, 2021 Filed May 19, 2021 20:30 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionPerformance Rights · Derivative | 17,193 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-008301 · doc4.xml · derivative · entry 5 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,193 shares Expires 2025-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 17, 2018, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 3, 2021, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 17, 2021, and the actual number of shares vested are reflected on this Form 4. Read SEC document |
| May 17, 2021 Filed May 19, 2021 20:30 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 8,525 | $89.49 | $762,902.25 |
DisclosureSEC source: 0001225208-21-008301 · doc4.xml · nonDerivative · entry 3 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,131 Read SEC document |
| May 17, 2021 Filed May 19, 2021 20:30 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 1,643 | $89.49 | $147,032.07 |
DisclosureSEC source: 0001225208-21-008301 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,656 Read SEC document |
| May 17, 2021 Filed May 19, 2021 20:30 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 17,193 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-008301 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 17, 2018, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 3, 2021, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 17, 2021, and the actual number of shares vested are reflected on this Form 4. F1 · price: On May 17, 2018, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 3, 2021, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 17, 2021, and the actual number of shares vested are reflected on this Form 4. Read SEC document |
| May 11, 2021 Filed May 13, 2021 01:38 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 1,570 | $90.40 | $141,928.00 |
DisclosureSEC source: 0001225208-21-008057 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,106 Read SEC document |
| May 07, 2021 Filed May 11, 2021 21:15 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 538 | $91.75 | $49,361.50 |
DisclosureSEC source: 0001225208-21-007975 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,676 Read SEC document |
| May 04, 2021 Filed May 7, 2021 01:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantPerformance Rights · Derivative | 6,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-007706 · doc4.xml · derivative · entry 4 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,375 Underlying: Common Stock · 6,375 shares Expires 2028-05-03 F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 4, 2021 and scheduled to vest on May 4, 2024. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 04, 2021 Filed May 7, 2021 01:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 44,400 | $0.00 Strike: $93.31 | $0.00 |
DisclosureSEC source: 0001225208-21-007706 · doc4.xml · derivative · entry 3 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,400 Underlying: Common Stock · 44,400 shares Expires 2028-05-03 F2 · derivative.exercise_date: These options were granted on May 4, 2021 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 04, 2021 Filed May 7, 2021 01:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 5,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-007706 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,214 F1 · shares: These restricted stock units were granted on May 4, 2021 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| November 23, 2020 Filed Nov 24, 2020 21:28 UTC | BERRY GLOBAL GROUP, INC. BERY · Entity 80192 | GrantDirector Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $54.22 | $0.00 |
DisclosureSEC source: 0001567619-20-020278 · doc1.xml · derivative · entry 2 Ullem Scott B. · CIK 0001446989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,500 Underlying: Common Stock · 5,000 shares Expires 2030-11-22 F3 · derivative.exercise_date: Granted under the 2015 Long-Term Incentive Plan. Options vest in full on the first anniversary of the grant date. Read SEC document |
| November 23, 2020 Filed Nov 24, 2020 21:28 UTC | BERRY GLOBAL GROUP, INC. BERY · Entity 80192 | GrantRestricted Stock Units · Derivative | 1,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-020278 · doc1.xml · derivative · entry 1 Ullem Scott B. · CIK 0001446989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,667 Underlying: Common Stock · 1,667 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of BERY common stock. Granted under the 2015 Long-Term Incentive Plan. F2 · derivative.exercise_date: The restricted stock units vest in full on the first anniversary of the grant date. Shares of BERY common stock will be delivered to the reporting person within 60 days following the date on which the restricted stock units vest. F2 · derivative.expiration_date: The restricted stock units vest in full on the first anniversary of the grant date. Shares of BERY common stock will be delivered to the reporting person within 60 days following the date on which the restricted stock units vest. Read SEC document |
| October 26, 2020 Filed Oct 27, 2020 00:33 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 33,150 | $0.00 Strike: $21.76 | $0.00 |
DisclosureSEC source: 0001225208-20-012745 · doc4.xml · derivative · entry 5 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,150 shares Expires 2022-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2020. Read SEC document |
| October 26, 2020 Filed Oct 27, 2020 00:33 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 19,229 | $79.20 | $1,522,988.72 |
DisclosureSEC source: 0001225208-20-012745 · doc4.xml · nonDerivative · entry 3 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,114 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $78.8550 to $79.5200. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 26, 2020 Filed Oct 27, 2020 00:33 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 13,921 | $78.26 | $1,089,400.38 |
DisclosureSEC source: 0001225208-20-012745 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,343 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $77.8450 to $78.8300. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 26, 2020 Filed Oct 27, 2020 00:33 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 33,150 | $21.76 | $721,344.00 |
DisclosureSEC source: 0001225208-20-012745 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,264 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2020. Read SEC document |
| October 12, 2020 Filed Oct 13, 2020 22:09 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 33,150 | $0.00 Strike: $21.76 | $0.00 |
DisclosureSEC source: 0001225208-20-012447 · doc4.xml · derivative · entry 5 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,150 Underlying: Common Stock · 33,150 shares Expires 2022-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2020. Read SEC document |
| October 12, 2020 Filed Oct 13, 2020 22:09 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 27,500 | $83.69 | $2,301,543.75 |
DisclosureSEC source: 0001225208-20-012447 · doc4.xml · nonDerivative · entry 3 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,114 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $83.18 to $84.1650. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 12, 2020 Filed Oct 13, 2020 22:09 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,650 | $84.37 | $476,672.99 |
DisclosureSEC source: 0001225208-20-012447 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,614 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $84.17 to $84.61. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 12, 2020 Filed Oct 13, 2020 22:09 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 33,150 | $21.76 | $721,344.00 |
DisclosureSEC source: 0001225208-20-012447 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,264 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2020. Read SEC document |
| September 28, 2020 Filed Sep 29, 2020 01:04 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 33,150 | $0.00 Strike: $21.76 | $0.00 |
DisclosureSEC source: 0001225208-20-011862 · doc4.xml · derivative · entry 4 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,300 Underlying: Common Stock · 33,150 shares Expires 2022-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2020. Read SEC document |
| September 28, 2020 Filed Sep 29, 2020 01:04 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 33,150 | $78.11 | $2,589,203.96 |
DisclosureSEC source: 0001225208-20-011862 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,114 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $77.71 to $78.51. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 28, 2020 Filed Sep 29, 2020 01:04 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 33,150 | $21.76 | $721,344.00 |
DisclosureSEC source: 0001225208-20-011862 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,264 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2020. Read SEC document |
| September 15, 2020 Filed Sep 15, 2020 22:05 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 33,150 | $0.00 Strike: $21.76 | $0.00 |
DisclosureSEC source: 0001225208-20-011594 · doc4.xml · derivative · entry 4 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,450 Underlying: Common Stock · 33,150 shares Expires 2022-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2020. Read SEC document |
| September 15, 2020 Filed Sep 15, 2020 22:05 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 33,150 | $83.43 | $2,765,747.60 |
DisclosureSEC source: 0001225208-20-011594 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,114 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $82.94 to $83.84. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 15, 2020 Filed Sep 15, 2020 22:05 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 33,150 | $21.76 | $721,344.00 |
DisclosureSEC source: 0001225208-20-011594 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,264 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2020. Read SEC document |
| September 14, 2020 Filed Sep 14, 2020 22:26 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 26,700 | $0.00 Strike: $13.98 | $0.00 |
DisclosureSEC source: 0001225208-20-011538 · doc4.xml · derivative · entry 4 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,700 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2020. Read SEC document |
| September 14, 2020 Filed Sep 14, 2020 22:26 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 26,700 | $82.21 | $2,194,908.21 |
DisclosureSEC source: 0001225208-20-011538 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,114 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $81.9900 to $82.5450. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 14, 2020 Filed Sep 14, 2020 22:26 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 26,700 | $13.98 | $373,266.00 |
DisclosureSEC source: 0001225208-20-011538 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,814 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2020. Read SEC document |
| August 06, 2020 Filed Aug 6, 2020 21:49 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 26,700 | $0.00 Strike: $13.98 | $0.00 |
DisclosureSEC source: 0001225208-20-010370 · doc4.xml · derivative · entry 4 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,700 Underlying: Common Stock · 26,700 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 22, 2020. Read SEC document |
| August 06, 2020 Filed Aug 6, 2020 21:49 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 26,700 | $77.31 | $2,064,088.89 |
DisclosureSEC source: 0001225208-20-010370 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,114 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 22, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $77.10 to $77.76. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 06, 2020 Filed Aug 6, 2020 21:49 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 26,700 | $13.98 | $373,266.00 |
DisclosureSEC source: 0001225208-20-010370 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,814 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 22, 2020. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 01:04 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 26,700 | $0.00 Strike: $13.98 | $0.00 |
DisclosureSEC source: 0001225208-20-009652 · doc4.xml · derivative · entry 4 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,400 Underlying: Common Stock · 26,700 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 22, 2020. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 01:04 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 26,700 | $69.98 | $1,868,388.57 |
DisclosureSEC source: 0001225208-20-009652 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,114 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 22, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $69.74 to $70.27. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 01:04 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 26,700 | $13.98 | $373,266.00 |
DisclosureSEC source: 0001225208-20-009652 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,814 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 22, 2020. Read SEC document |
| June 22, 2020 Filed Jun 22, 2020 21:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 26,700 | $0.00 Strike: $13.98 | $0.00 |
DisclosureSEC source: 0001225208-20-009143 · doc4.xml · derivative · entry 6 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,100 Underlying: Common Stock · 26,700 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 22, 2020. Read SEC document |
| June 22, 2020 Filed Jun 22, 2020 21:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 24,479 | $69.45 | $1,700,037.18 |
DisclosureSEC source: 0001225208-20-009143 · doc4.xml · nonDerivative · entry 4 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,114 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 22, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $69.04 to $69.99. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 22, 2020 Filed Jun 22, 2020 21:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,221 | $70.19 | $155,891.32 |
DisclosureSEC source: 0001225208-20-009143 · doc4.xml · nonDerivative · entry 3 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,593 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 22, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $70.0450 to $70.22. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 22, 2020 Filed Jun 22, 2020 21:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 26,700 | $13.98 | $373,266.00 |
DisclosureSEC source: 0001225208-20-009143 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,814 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 22, 2020. Read SEC document |
| May 29, 2020 Filed Jun 22, 2020 21:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 14,487 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-009143 · doc4.xml · nonDerivative · entry 5 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 229,251 F1 · shares: On May 29, 2020, the Insider transferred into his trust 14,487 common shares, which reflects the 3-for-1 stock split that occurred on the same day. Read SEC document |
| May 29, 2020 Filed Jun 22, 2020 21:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 14,487 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-009143 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,114 F1 · shares: On May 29, 2020, the Insider transferred into his trust 14,487 common shares, which reflects the 3-for-1 stock split that occurred on the same day. Read SEC document |
| May 12, 2020 Filed May 13, 2020 20:17 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 726 | $225.05 | $163,386.30 |
DisclosureSEC source: 0001225208-20-007578 · doc4.xml · nonDerivative · entry 4 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,867 Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:17 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionPerformance Rights · Derivative | 6,606 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007578 · doc4.xml · derivative · entry 6 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,606 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form. F1 · derivative.exercise_date: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form. F1 · derivative.expiration_date: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form. F1 · derivative.underlying_shares: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form. Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:17 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 3,276 | $217.84 | $713,643.84 |
DisclosureSEC source: 0001225208-20-007578 · doc4.xml · nonDerivative · entry 3 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,593 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.